IGF-1, IGF-2, and IGFBP-1,2,3 were assayed in blood serum of patients with malignant ovarian tumors (n=44), borderline ovarian tumors (n=11), and benign ovarian tumors (n=12) as well as in healthy women (n=33). In blood serum of patients with malignant ovarian tumors, the level of IGF-1 was lower and IGFBP-1 was higher than in other groups. In patients with malignant and borderline ovarian tumors, the level of IGFBP-2 was higher than in healthy women and in patients with benign ovarian tumors. There was no correlation between most examined parameters and the clinical and morphological peculiarities of ovarian tumors. The study revealed IGF/IGFBP imbalance in patients with malignant ovarian tumor and showed that IGFBP-2 proved to be a potential diagnostic serological marker w with 90% sensitivity and 90% specificity.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
L. I. Korolenkova, D. N. Kushlinsky, E. S. Gershtein, et al., Vopr. Biol. Med. Farmakol. Khim., No. 10, 21-25 (2012).
A. V. Maslyaev, O. I. Kostyleva, E. S. Gershtein, et al., Vopr. Biol. Med. Farmakol. Khim., No. 10, 16-20 (2012).
S. Baron-Hay, F. Boyle, A. Ferrier, and C. Scott, Clin. Cancer Res., 10, No. 5, 1796-1806 (2004).
M. C. Beauchamp, A. Yasmeen, A. Knafo, and W. H. Gotlieb, J. Oncol., 2010, doi: 10.1155/2010/257058 (2010).
J. Brokaw, D. Katsaros, A. Wiley, et al., Growth Factors, 25, No. 5, 346-354 (2007).
I. Bruchim and H. Werner, Expert Opin. Ther. Targets, 17, No. 3, 307-320 (2013).
R. Druckmann and U. D. Rohr, Maturitas, 41, Suppl. 1, S65-S83 (2002).
G. S. Huang, J. Brouwer-Visser, M. J. Ramirez, et al., Clin. Cancer Res., 16, No. 11, 2999-3010 (2010).
D. Katsaros, H. Yu, M. A. Levesque, et al., Eur. J. Cancer., 37, No. 4, 478-485 (2001).
P. H. Peeters, A. Lukanova, N. Allen, et al., Endocr. Relat. Cancer., 14, No. 1, 81-90 (2007).
R. A. Sayer, J. M. Lancaster, J. Pittman, et al., Gynecol. Oncol., 96, No. 2, 355-361 (2005).
D. Spentzos, S. A. Cannistra, F. Grall, et al., Endocr. Relat. Cancer, 14, No. 3, 781-790 (2007).
S. S. Tworoger, I. M. Lee, J. E. Buring, et al., Cancer Epidemiol. Biomarkers Prev., 16, No. 8, 1691-1695 (2007).
B. Waksmanski, J. Dudkiewicz, and T. Kowalski, Med. Sci. Monit., 7, No. 5, 919-923 (2001).
S. N. Westin, T. J. Herzog, and R. L. Coleman, Invest. New Drugs, 31, No. 1, 213-229 (2012).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 160, No. 12, pp. 787-790, December, 2015
Rights and permissions
About this article
Cite this article
Gershtein, E.S., Isaeva, E.R., Kushlinsky, D.N. et al. Insulin-Like Growth Factors (IGF) and IGF-Binding Proteins (IGFBP) in the Serum of Patients with Ovarian Tumors. Bull Exp Biol Med 160, 814–816 (2016). https://doi.org/10.1007/s10517-016-3317-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-016-3317-2